IL-13 Antibody (32116.11): sc-57261

IL-13 Antibody (32116.11) is a mouse monoclonal IgG1 antibody that detects interleukin-13 in human samples through applications such as western blotting (WB) and enzyme-linked immunosorbent assay (ELISA). IL-13 is a pleiotropic cytokine that plays a crucial role in immune regulation and inflammation, exhibiting approximately 30% sequence identity with interleukin-4 and sharing many biological activities. Anti-IL-13 antibody (32116.11) recognizes a cytokine secreted by activated T lymphocytes that significantly influences monocytes, macrophages, and B cells by upregulating the expression of CD23 and major histocompatibility complex (MHC) proteins while downregulating CD14 expression. Notably, IL-13 is involved in inhibiting the secretion of pro-inflammatory cytokines and chemokines from activated monocytes, as well as stimulating IgE expression on activated B cells, which is vital for allergic responses and asthma pathogenesis. IL-13 (32116.11) monoclonal antibody targets a protein structure that includes five cysteine residues and multiple N-linked glycosylation sites, which are essential for its stability and biological activity. The cDNA of IL-13 encodes a 131 amino acid precursor that contains a 20 amino acid signal peptide, which is cleaved to produce the mature protein, highlighting the importance of post-translational modifications in its functional regulation. With its significant role in modulating immune responses, anti-IL-13 antibody (32116.11) is an invaluable tool for researchers studying cytokine signaling and related pathways in human health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IL-13 Antibody (32116.11) References:

1. Commonality of the IL-4/IL-13 pathway in atopic diseases.  |  Gandhi, NA., et al. 2017. Expert Rev Clin Immunol. 13: 425-437. PMID: 28277826
2. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes.  |  Junttila, IS. 2018. Front Immunol. 9: 888. PMID: 29930549
3. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis.  |  Tsoi, LC., et al. 2019. J Invest Dermatol. 139: 1480-1489. PMID: 30641038
4. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets.  |  Nguyen, JK., et al. 2020. Arch Dermatol Res. 312: 81-92. PMID: 31493000
5. Epithelial miR-141 regulates IL-13-induced airway mucus production.  |  Siddiqui, S., et al. 2021. JCI Insight. 6: PMID: 33682796
6. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis.  |  Dubin, C., et al. 2021. Expert Rev Clin Immunol. 17: 835-852. PMID: 34106037
7. Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis.  |  Iwaszko, M., et al. 2021. Cells. 10: PMID: 34831223
8. Engineering the IL-4/IL-13 axis for targeted immune modulation.  |  Bernstein, ZJ., et al. 2023. Immunol Rev. 320: 29-57. PMID: 37283511
9. Epithelial overexpression of IL-33 induces eosinophilic esophagitis dependent on IL-13.  |  Masuda, MY., et al. 2024. J Allergy Clin Immunol. 153: 1355-1368. PMID: 38310974
10. IL-13 facilitates ferroptotic death in asthmatic epithelial cells via SOCS1-mediated ubiquitinated degradation of SLC7A11.  |  Miao, M., et al. 2024. Redox Biol. 71: 103100. PMID: 38484644

The preferred IL-13 antibody is IL-13 Antibody (A-9): sc-393365.